Oral

[O3-5] SARS2-7

Tue. Nov 15, 2022 1:00 PM - 2:30 PM Room 5 (Conference Room 109)

Chair:Takao Hashiguchi(Kyoto University), Akatsuki Saito(Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki)

+Add all to schedule

1:00 PM - 1:15 PM

[O3-5-1] Structural basis for the recognition of SARS-CoV-2 spike by potent neutralizing antibody NT-108

*Yuki Anraku¹, Taishi Onodera², Shunsuke Kita¹, Yu Adachi², Saya Moriyama², Akihiko Sato^3,4, Takao Nomura¹, Takashi Tadokoro^1,5, Kohei Yumoto^1,2, Shiori Ito¹, Cong Tian¹, Hideo Fukuhara^1,3, Michihito Sasaki³, Yasuko Orba³, Nozomi Shiwa², Naoko Iwata², Noriyo Nagata², Tateki Suzuki⁶, Jiei Sasaki⁶, Tsuyoshi Sekizuka², Keisuke Tonouchi², Shuetsu Fukushi², Hiroyuki Satofuka⁷, Yasuhiro Kazuki⁷, Lin Sun², Mitsuo Oshimura⁸, Makoto Kuroda², Tadaki Suzuki², Hirofumi Sawa³, Takao Hashiguchi⁶, Yoshimasa Takahashi², Katsumi Maenaka¹ (1. Faculty of Pharmaceutical Sciences, Hokkaido University, 2. National Institute of Infectious Diseases, 3. Division of Molecular Pathobiology, Research Center for Zoonosis Control, 4. Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., 5. Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 6. Institute for Frontier Life and Medical Sciences, Kyoto University, 7. Chromosome Engineering Research Center, Tottori University, 8. Trans Chromosomics Inc.)

1:15 PM - 1:30 PM

[O3-5-2] Structural dynamics of SARS-CoV-2 spike (S) protein and its interaction with ACE2 receptor and small extracellular vesicles.

*Kee Siang Lim¹, Goro Nishide², Takeshi Yoshida⁴, Takahiro Watanabe-Nakayama¹, Akiko Kobayashi³, Masaharu Hazawa^1,3, Rikinari Hanayama^1,4, Toshio Ando¹, Richard W. Wong^1,3 (1. Kanazawa University. WPI-Nano Life Science Institute, 2. Kanazawa University. Division of Nano Life Science in the Graduate School of Frontier Science Initiative, WISE Program for Nano-Precision Medicine, Science and Technology, 3. Kanazawa University. Cell-Bionomics Research Unit, Institute for Frontier Science Initiative (INFINITI), 4. Kanazawa University. Department of Immunology, Graduate School of Medical Sciences)

1:30 PM - 1:45 PM

[O3-5-3] Structural basis for neutralization of a pan-SARS-CoV-2 antibody and ACE2 recognition by BA.4/5 variants

Tateki Suzuki¹, Yuki Anraku², Kanako Kimura¹, Shunsuke Kita², Jiei Sasaki¹, Tatsuhiko Ozawa³, HIdeki Niimi³, Kei Sato⁴, Katsumi Maenaka², *Takao Hashiguchi¹ (1. Kyoto University, 2. Hokkaido University, 3. University of Toyama, 4. The University of Tokyo)

1:45 PM - 2:00 PM

[O3-5-4] Mechanism of cross-species transmission of SARS-CoV-2

*Yuuka Nitta¹, Moe Nishimoto¹, Noriko Arimitsu¹, Minami Nagai¹, Miyu Moriyama², Takeshi Ichinohe¹ (1. Institute of Medical Science, The University of Tokyo, 2. Yale University)

2:00 PM - 2:15 PM

[O3-5-5] Establishment of a human lung cell culture model for the development of anti-viral drugs against SARS-CoV-2

*Mitsuhisa Nariyama^1,2, Hikaru Inaba^1,2, Rahmi Dianty^1,2, Kentaro Uemura^1,2, Hiroyuki Mori^1,2, saya nakagomi^1,2, Chikako Ono^1,2, Shuhei Taguwa^1,2, Yoshiharu Matsuura^1,2 (1. Virus Control, CiDER, Osaka Univ., 2. Virus Control, RIMD, Osaka Univ.)

2:15 PM - 2:30 PM

[O3-5-6] Association of virological properties of SARS-CoV-2 Omicron BA.1 variant with mutations of spike protein

*Yusuke Kosugi¹, Keiya Uriu¹, Jiri Zahradnik², Hesham Nasser³, Terumasa Ikeda³, Kei Sato¹ (1. Division of Systems Virology, Department of Infectious Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., 2. Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel., 3. Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan)

Session information